# OnCo record zimberelimab (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/zimberelimab/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "zimberelimab" ;
  schema:name "Zimberelimab"@en ;
  schema:alternateName "AB122"@en ;
  schema:description "Zimberelimab is a PD-1 antibody approved in China in 2021 for relapsed classical Hodgkin lymphoma, and the checkpoint partner in Arcus and Gilead's Western trials of the TIGIT antibody domvanalimab."@en ;
  schema:url <https://onco.cc/drugs/zimberelimab/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/search?intr=GLS-010> ;
  onco:status "approved" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Anti-PD-1 monoclonal antibody, intravenous" ;
  onco:approval "CN 2021: Relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy" ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/cervical/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:targets <https://onco.cc/targets/pd1/> ;
  onco:companies <https://onco.cc/companies/arcus-biosciences/> ;
  onco:trials <https://onco.cc/trials/nct05798819/>, <https://onco.cc/trials/nct05633667/>, <https://onco.cc/trials/nct05676931/>, <https://onco.cc/trials/nct04736173/>, <https://onco.cc/trials/nct06727565/>, <https://onco.cc/trials/nct06155396/>, <https://onco.cc/trials/nct05909436/>, <https://onco.cc/trials/nct07710885/>, <https://onco.cc/trials/nct03547973/>, <https://onco.cc/trials/nct05329766/> .